Select your Market

Global
Global
CAREERS

First Quarter: Strong Start into Fiscal 2022

Our growth story continues to materialize. Group sales increased organically by 7.8% to € 5.2 billion compared with the year-earlier quarter.

Key facts and Forecast

Results of Q1 2022

  • Group sales increase by 12.2% to € 5.2 billion; EBITDA pre up 7.8% to € 1.6 billion; EBITDA pre margin 31.3%
  • Growth story continues to materialize
  • High margins in all three businesses despite challenging economic headwinds and increasing global uncertainty

Forecast for fiscal 2022

  • Company specifies forecast for net sales, EBITDA pre and earnings per share pre
  • Net sales between € 21.6 billion and € 22.8 billion; EBITDA pre in a range between € 6.6 billion and € 7.1 billion; earnings per share pre between € 9.60 and € 10.50

Overview: Business performance in Q1 2022

       

Group net sales:

€ 5.2 bn.

+12.2%

(organic: +7.8%)

EBITDA pre:

€ 1.6 bn.

+7.8%

(organic: +1.6%)

Life Science:

€ 2.4 bn.

+14.7%

(organic: +9.7%)

Healthcare:

€ 1.8 bn.

+9.5%

(organic: +6.5%)

Electronics:

€ 957 m.

+11.2%

(organic: +5.2%)

Belén Garijo - Chair of the Executive Board and CEO of Merck KGaA, Darmstadt, Germany

We have made a promising start to 2022, with our Big 3 generating strong growth and attractive margins.

Belén Garijo

Chair of the Executive Board and CEO of Merck KGaA, Darmstadt, Germany

  • Quarterly Statement Q1 2022 Brochure Quarterly Statement Q1 2022 Brochure

    Quarterly Statement Q1 2022

    Detailed information about our business in the first quarter of 2022.
    Download (PDF)

ADDITIONAL INFORMATION

Financial Report
 

Downloads for the Media

Additional Downloads

Annual Reports Archive

Find previous Annual Reports, Corporate Governance Reports & Statements in our archive.
Read more